RxDoctor Payments Data

Jacquelyn McFadden, MD

Internal Medicine · Florissant, MONPI 1891809646

Payments from drug & device makers

$2,921in general payments, 2019–2025

Across 174 payments — averaging $16.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$818
  • Novo Nordisk$772
  • Astellas Pharma US Inc$244
  • Pfizer$199
  • Exact Sciences$109
  • Sunovion Pharmaceuticals Inc.$99
  • plus $681 from 14 others

What the payments were for

  • Food & beverage$2,912100%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,921 in reported general payments places this provider in the 80th percentile of 2,097 internal medicine providers in Missouri.

See all internal medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$3,749
Medicare patients
79
Services billed
256

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide129$146,987
OzempicSemaglutide77$89,373
JardianceEmpagliflozin70$75,482
RybelsusSemaglutide19$32,064
JanuviaSitagliptin Phosphate29$31,916
EliquisApixaban43$30,075
MounjaroTirzepatide29$29,828
MyrbetriqMirabegron26$22,975
XareltoRivaroxaban22$22,370
TradjentaLinagliptin19$16,351
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$14,315
FarxigaDapagliflozin Propanediol21$13,847
Lantus SolostarInsulin Glargine,hum.Rec.Anlog101$10,274
SymbicortBudesonide/Formoterol Fumarate28$9,173
Levemir FlexpenInsulin Detemir48$8,504

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$818$176,815158 claims
Novo NordiskOzempic, Rybelsus$772$121,43896 claims
Boehringer IngelheimJardiance, Tradjenta$19$91,83389 claims
MerckJanuvia, Belsomra$45$39,91747 claims
PfizerEliquis$199$30,07543 claims
AstraZenecaFarxiga, Symbicort$96$23,02149 claims
Astellas Pharma US IncMyrbetriq$244$22,97526 claims
GSKTrelegy Ellipta$66$14,31520 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,097 internal medicine providers in Missouri.

Other internal medicine in Florissant

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →